Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Supernus Pharmaceuticals Inc

+ Add to Watchlist


13.4700 USD 0.0200 0.15%

As of 20:10:00 ET on 04/17/2015.

Snapshot for Supernus Pharmaceuticals Inc (SUPN)

Open: 13.3800 Day's Range: 13.3300 - 13.5400 Volume: 573,067
Previous Close: 13.4900 52wk Range: 7.0901 - 13.6800 1-Yr Rtn: +63.08%

Stock Chart for SUPN

No chart data available.
  • SUPN:US 13.4700
  • 1D
  • 1M
  • 1Y
Interactive SUPN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SUPN

Current P/E Ratio (ttm) 30.3918
Estimated P/E(12/2015) 101.2782
Relative P/E vs. SPX 1.6546
Earnings Per Share (USD) (ttm) 0.4432
Est. EPS (USD) (12/2015) 0.1330
Est. PEG Ratio -
Market Cap (M USD) 630.12
Shares Outstanding (M) 46.78
30 Day Average Volume 884,224
Price/Book (mrq) 8.1126
Price/Sale (ttm) 4.6977
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SUPN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for SUPN

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. Supernus has developed a portfolio of clinical stage drugs to address neurological and psychological problems such as epilepsy, conduct disorder, Parkinson's disease, ADHD, depression and anxiety.

Jack A KhattarPresident/CEO/Secy/FounderStefan K F SchwabeExec VP:R&D/Chief Medical Ofcr
Padmanabh P BhattSenior VP:Intellectual PropertyVictor VaughnSenior VP:Sales
More Company Profile & Key Executives for SUPN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil